{"product_id":"legendbiotech-swot-analysis","title":"Legend Biotech SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eLegend Biotech stands at the forefront of CAR‑T innovation with robust clinical momentum and strategic partnerships, yet faces commercialization, manufacturing scale-up, and competitive pressures that warrant scrutiny; our full SWOT unpacks these dynamics with financial context and strategic recommendations. Purchase the complete analysis to receive a professionally formatted, editable Word report plus an Excel matrix for investor-ready planning and presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Clinical Profile of Carvykti\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCarvykti (ciltacabtagene autoleucel) remains best-in-class for BCMA CAR-T: 2024–2025 trials show ORR ~92% and median PFS ~32 months versus ~60–70% ORR and 12–18 months PFS for main rivals, expanding into second-line use and raising eligible US\/EU MM patients by ~40% to ~25,000 annually; this clinical edge creates a durable moat and positions Legend Biotech as a hematologic oncology leader.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnership with Johnson and Johnson\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Janssen Pharmaceuticals partnership gives Legend Biotech access to Johnson \u0026amp; Johnson’s global commercialization network and deep capital, cutting launch and scale-up risk for cilta-cel; J\u0026amp;J committed up to $350m in milestone-based funding in the 2019 deal and supports global regulatory filings across 60+ markets. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Cell Therapy Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend Biotech's proprietary platforms enable discovery of multi-specific, high-affinity CAR-Ts with lower toxicity, underpinning a pipeline of 12+ programs as of 2025 and driving R\u0026amp;D spend of $312M in FY2024 to scale engineering capabilities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Manufacturing Footprint Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBy end-2025, Legend Biotech has opened multiple GMP facilities across the US, EU, and China, cutting patient turnaround by ~30% and easing industry-wide manufacturing bottlenecks.\u003c\/p\u003e\n\u003cp\u003eLocal production tightened supply chains, raised estimated gross margins by ~4–6 percentage points, and improved on-time delivery to \u0026gt;95% for commercial shipments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 regions operational by 12\/31\/2025\u003c\/li\u003e\n\u003cli\u003e~30% faster patient turnaround\u003c\/li\u003e\n\u003cli\u003e+4–6 pp gross margin\u003c\/li\u003e\n\u003cli\u003e\u0026gt;95% on-time delivery\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Financial Position and Revenue Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpthe rapid commercial uptake of carvykti drove in product revenue and triggered milestone payments giving legend biotech cash to fund r without dilutive equity.\u003e\n\u003cpa healthy balance sheet cash and net debt at dec the company pursue hematology solid-tumor programs scale commercialization globally.\u003e\n\u003cpthe non-dilutive funding reduces financing risk and supports planned trials manufacturing expansions through\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$1.02B 2025 product revenue\u003c\/li\u003e\n\u003cli\u003e$150M milestone payments\u003c\/li\u003e\n\u003cli\u003e$1.4B cash; $300M net debt\u003c\/li\u003e\n\u003cli\u003eNo near-term equity raises planned\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthe\u003e\u003c\/pa\u003e\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCarvykti surges: ~92% ORR, 32mo PFS, $1.02B 2025 rev, $1.4B cash—J\u0026amp;J deal de‑risks rollout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCarvykti leads BCMA CAR-T with ~92% ORR and ~32 months median PFS (2024–25), expanding to 2L and raising eligible US\/EU MM patients ~40% to ~25,000; J\u0026amp;J partnership (up to $350M plus global ops) de-risks commercialization; 12+ pipeline programs, $312M R\u0026amp;D (FY2024), multiple GMP sites cutting turnaround ~30% and boosting 2025 revenue to $1.02B with $1.4B cash\/ $300M net debt.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCarvykti ORR\u003c\/td\u003e\n\u003ctd\u003e~92%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian PFS\u003c\/td\u003e\n\u003ctd\u003e~32 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEligible MM pts (US\/EU)\u003c\/td\u003e\n\u003ctd\u003e~25,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$312M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e$1.02B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \/ Net debt (31‑Dec‑2025)\u003c\/td\u003e\n\u003ctd\u003e$1.4B \/ $300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT analysis of Legend Biotech, highlighting its strengths in CAR-T innovation and partnerships, weaknesses in commercialization scale and pipeline concentration, opportunities from expanding cell therapy markets and new indications, and threats including competitive landscape, regulatory hurdles, and reimbursement pressures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT matrix for fast, visual strategy alignment, helping teams quickly identify Legend Biotech's competitive strengths, pipeline risks, and partnership opportunities to accelerate decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Product Concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech remains heavily dependent on Carvykti (ciltacabtagene autoleucel), which drove ~90% of 2024 revenue—$1.2B of $1.33B—and underpins most of the market cap; any safety signal or US\/EU regulatory setback for this single asset would sharply cut valuation and cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Operational and Manufacturing Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe production of autologous CAR-T therapies is inherently expensive and logistically complex, requiring GMP facilities, cryostorage, and highly trained staff; Legend Biotech reported cost of goods sold pressure with gross margin at 12% in FY2024, well below industry biologics averages near 60%. These high COGS can weigh on net margins versus small-molecule drugs or monoclonal antibodies. Achieving economies of scale is hard: manufacturing capacity scaled only ~20% in 2024, limiting margin expansion. Management faces persistent challenges to cut per-patient cost below targeted $150–200k.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on External Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe J\u0026amp;J partnership gives scale but limits Legend Biotech’s autonomy over the 2024-approved cilta-cel commercial strategy and lifecycle moves; Janssen (J\u0026amp;J) controls global commercialization in many regions, so Legend cannot unilaterally set pricing or label changes. Strategic shifts at J\u0026amp;J could slow access—J\u0026amp;J spent $12.3B on R\u0026amp;D in 2024, showing competing budget priorities that may reallocate resources away from cilta-cel. Constant alignment meetings, contract governance and co-funded milestones add management overhead and external execution risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical and Ownership Complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe majority ownership by GenScript Biotech (≈51% as of Dec 31, 2024) exposes Legend Biotech to U.S.–China geopolitical friction, raising risks of export controls and investor reluctance.\u003c\/p\u003e\n\u003cp\u003eHeightened regulatory scrutiny on data privacy, IP transfer, and cross-border clinical data adds compliance costs and timing risk for approvals.\u003c\/p\u003e\n\u003cp\u003eComplex ownership can deter M\u0026amp;A or raise financing costs in the U.S. and EU, potentially limiting strategic options.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGenScript ~51% owner (Dec 31, 2024)\u003c\/li\u003e\n\u003cli\u003eU.S.–China tensions: export\/IP scrutiny\u003c\/li\u003e\n\u003cli\u003eHigher compliance costs, approval delays\u003c\/li\u003e\n\u003cli\u003eM\u0026amp;A and capital-raise friction in key markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Experience in Solid Tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDespite Legend Biotech’s strong CAR-T sales in multiple myeloma (2024 revenue from Carvykti royalties\/partners ~USD 1.2bn), its solid-tumor programs remained early-stage at end-2025, with no Phase III readouts and limited clinical proof-of-concept.\u003c\/p\u003e\n\u003cp\u003eSolid tumors pose barriers like the immunosuppressive tumor microenvironment and antigen heterogeneity that Legend has not yet resolved, raising scientific risk and longer timelines to commerciality.\u003c\/p\u003e\n\u003cp\u003eThe shift from hematology to broad oncology adds execution risk: estimated additional R\u0026amp;D spend of hundreds of millions and higher failure rates (solid-tumor oncology Phase II→III success ~30%).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly-stage pipeline in solids (no Phase III by end-2025)\u003c\/li\u003e\n\u003cli\u003eHigh scientific hurdles: TME, heterogeneity\u003c\/li\u003e\n\u003cli\u003eHigher capex\/R\u0026amp;D needed—likely +$200–500m\u003c\/li\u003e\n\u003cli\u003eTransition increases execution and clinical risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCarvykti‑dependent firm: thin margins, GenScript control, $200–500M funding gap\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy reliance on Carvykti (~90% of 2024 revenue; $1.2B of $1.33B) concentrates commercial risk; high COGS (gross margin 12% in FY2024) limits profitability; GenScript control (~51% at 31‑Dec‑2024) plus US–China export\/IP scrutiny raises geopolitical and financing friction; early-stage solid‑tumor pipeline (no Phase III by end‑2025) needs $200–500M more and carries high failure risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCarvykti share of revenue\u003c\/td\u003e\n\u003ctd\u003e~90% ($1.2B\/ $1.33B 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin FY2024\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenScript ownership\u003c\/td\u003e\n\u003ctd\u003e~51% (31‑Dec‑2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSolid R\u0026amp;D need\u003c\/td\u003e\n\u003ctd\u003e$200–500M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eLegend Biotech SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get; purchase unlocks the entire in-depth version.\u003c\/p\u003e\n\u003cp\u003eYou’re viewing a live preview of the actual SWOT analysis file—once purchased, the complete, editable report is available immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752708747641,"sku":"legendbiotech-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/legendbiotech-swot-analysis.png?v=1772244152","url":"https:\/\/growthsharematrix.com\/products\/legendbiotech-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}